F/M Emerald Life Sciences Innovation ETF (LFSC)

Assets	$126.71M
Expense Ratio	0.54%
PE Ratio	n/a
Shares Out	2.76M
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	2,761
Open	46.40
Previous Close	47.50
Day's Range	45.96 - 46.40
52-Week Low	27.67
52-Week High	48.78
Beta	n/a
Holdings	40
Inception Date	Oct 31, 2024

About LFSC

Fund Home Page

The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: NASDAQ
• Ticker Symbol: LFSC
• ETF Provider: F/m Investments

Top 10 Holdings

56.66% of assets

Name	Symbol	Weight
Travere Therapeutics, Inc.	TVTX	8.43%
Spyre Therapeutics, Inc.	SYRE	7.58%
Cogent Biosciences, Inc.	COGT	7.01%
LivaNova PLC	LIVN	6.50%
Corcept Therapeutics Incorporated	CORT	6.46%
Guardant Health, Inc.	GH	5.86%
Mirum Pharmaceuticals, Inc.	MIRM	4.67%
Cytokinetics, Incorporated	CYTK	3.62%
BillionToOne, Inc.	BLLN	3.34%
Axsome Therapeutics, Inc.	AXSM	3.20%

Performance

LFSC had a total return of 64.80% in the past year, including dividends. Since the fund's inception, the average annual return has been 39.58%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Aug 29, 2026

Data Sources Report a data error